ZD 158252
Latest Information Update: 19 Jun 2001
At a glance
- Originator Bayer Schering Pharma
- Class Antipsoriatics
- Mechanism of Action Leukotriene B4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 19 Jun 2001 No-Development-Reported for Psoriasis in Germany (Unknown route)
- 23 Jan 1998 New profile
- 23 Jan 1998 Preclinical development for Psoriasis in Germany (Unknown route)